Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

Leerink analyst Andrew Berens upgraded Compass Therapeutics (CMPX) to Outperform from Market Perform with a price target of $6, up from $4, ...

In a report released on March 31, Andrew Berens from Leerink Partners maintained a Hold rating on IDEAYA Biosciences (IDYA – Research Report).

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of AxoGen in a research note issued to investors ...

Investment analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Turnstone Biologics in a report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges around ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

As of March 4, 2025, the average one-year price target for CorMedix is $16.52/share. The forecasts range from a low of $12.12 to a high of $19.95. The average price target represents an increase ...

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event. MindMed is a late-stage clinical ...